Segui
Giampaolo Tortora
Giampaolo Tortora
Medical Oncology- Fondazione Policlinico Universitario Gemelli-IRCCS Roma
Email verificata su policlinicogemelli.it
Titolo
Citata da
Citata da
Anno
Genomic analyses identify molecular subtypes of pancreatic cancer
P Bailey, DK Chang, K Nones, AL Johns, AM Patch, MC Gingras, ...
Nature 531 (7592), 47-52, 2016
32392016
Whole genomes redefine the mutational landscape of pancreatic cancer
N Waddell, M Pajic, AM Patch, DK Chang, KS Kassahn, P Bailey, ...
Nature 518 (7540), 495-501, 2015
26612015
EGFR antagonists in cancer treatment
F Ciardiello, G Tortora
New England Journal of Medicine 358 (11), 1160-1174, 2008
26442008
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
AV Biankin, N Waddell, KS Kassahn, MC Gingras, LB Muthuswamy, ...
Nature 491 (7424), 399-405, 2012
22052012
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ...
New England Journal of Medicine 381 (4), 317-327, 2019
20112019
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
F Ciardiello, G Tortora
Clinical Cancer Research 7 (10), 2958-2970, 2001
14252001
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ...
Clinical Cancer Research 6 (5), 2053-2063, 2000
13052000
Whole-genome landscape of pancreatic neuroendocrine tumours
A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ...
Nature 543 (7643), 65-71, 2017
8732017
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ...
Clinical cancer research 7 (5), 1459-1465, 2001
8162001
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ...
Cancer research 62 (24), 7284-7290, 2002
7132002
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ...
Nature genetics 45 (12), 1470-1473, 2013
7012013
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
D Goldstein, RH El-Maraghi, P Hammel, V Heinemann, V Kunzmann, ...
Journal of the National Cancer Institute 107 (2), dju413, 2015
6982015
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ...
JAMA oncology 4 (11), 1543-1552, 2018
6952018
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
G Di Lorenzo, G Tortora, FP D’Armiento, G De Rosa, S Staibano, ...
Clinical cancer research 8 (11), 3438-3444, 2002
6092002
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ...
Annals of Oncology 29 (9), 1895-1902, 2018
5552018
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in …
L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Caliò, ...
PloS one 10 (6), e0130142, 2015
5272015
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense …
F Ciardiello, R Bianco, V Damiano, G Fontanini, R Caputo, G Pomatico, ...
Clinical Cancer Research 6 (9), 3739-3747, 2000
5202000
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises
F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ...
Cancer treatment reviews 41 (2), 114-121, 2015
4612015
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor …
F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ...
Clinical Cancer Research 9 (4), 1546-1556, 2003
4602003
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
F Ciardiello, R Bianco, V Damiano, S De Lorenzo, S Pepe, S De Placido, ...
Clinical Cancer Research 5 (4), 909-916, 1999
4351999
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20